ZBTB16-RARα-Positive Atypical Promyelocytic Leukemia: A Case Report. 2022

Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
Department of Hematology, Fundación Jiménez Díaz University Hospital, 28040 Madrid, Spain.

BACKGROUND The majority of patients with acute promyelocytic leukemia (APL) manifest a specific chromosomal translocation t(15;17)(q22;q21), characterized by the fusion of RARA and PML genes. However, a proportion of APL cases are due to variant translocations, being t(11;17) (q23;q21) the most common amongst them. With the major exception of ZBTB16-RARA t(11;17) APL, these variant APL cases present similar morphological features as classic APL and are characterized by a lack of differentiation response to retinoids. METHODS We describe the case of variant APL with the ZBTB16-RARA fusion gene, showing a distinct morphology of classical APL, characterized by crystalline intracytoplasmic inclusions in both peripheral blood (PB) and bone marrow (BM) patients' blasts. Our patient was treated with two courses of intensive chemotherapy, initiating maintenance treatment with all-trans retinoic acid (ATRA) on day twenty-eight of the second course. Our patient achieved complete remission (CR) once the intensive chemotherapy was combined with ATRA. CONCLUSIONS This is the second case described of APL with t(11;17) that showed crystalline intracytoplasmic inclusions. The finding of these morphological features may suggest the presence of a variant translocation with RARA, being that both cases described are related to the presence of t(11;17). Despite induction treatment with intensive chemotherapy that included a seven-day continuous treatment with cytarabine (200 mg/m2), plus daily idarubicin (12 mg/m2) during the first three days, our patient did not achieve complete remission (CR) until scheduled 3 + 7 regimen combined with ATRA treatment was established. This observation suggests that ATRA may be partially effective in some ZBTB16-RARA APLs.

UI MeSH Term Description Entries
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075722 Promyelocytic Leukemia Zinc Finger Protein A Kruppel-type transcription factor consisting of an N-terminal BTB DOMAIN and nine CYS2-HIS2 ZINC FINGERS. It localizes to the nucleus and regulates cell cycle progression and gene expression for tissue development and homeostasis; it may also function as an epigenetic regulator through its interactions with HISTONE DEACETYLASE. Genetic rearrangements involving the ZBTB16 gene are associated with ACUTE PROMYELOCYTIC LEUKEMIA. PLZF Protein,Promyelocytic Leukaemia Zinc Finger Protein,ZBTB16 Protein,Zinc Finger and BTB Domain Containing 16 Protein
D014178 Translocation, Genetic A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome. Chromosomal Translocation,Translocation, Chromosomal,Chromosomal Translocations,Genetic Translocation,Genetic Translocations,Translocations, Chromosomal,Translocations, Genetic
D014212 Tretinoin An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). Retinoic Acid,Vitamin A Acid,Retin-A,Tretinoin Potassium Salt,Tretinoin Sodium Salt,Tretinoin Zinc Salt,Vesanoid,all-trans-Retinoic Acid,beta-all-trans-Retinoic Acid,trans-Retinoic Acid,Acid, Retinoic,Acid, Vitamin A,Acid, all-trans-Retinoic,Acid, beta-all-trans-Retinoic,Acid, trans-Retinoic,Potassium Salt, Tretinoin,Retin A,Salt, Tretinoin Potassium,Salt, Tretinoin Sodium,Salt, Tretinoin Zinc,Sodium Salt, Tretinoin,Zinc Salt, Tretinoin,all trans Retinoic Acid,beta all trans Retinoic Acid,trans Retinoic Acid
D015473 Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION. Leukemia, Myeloid, Acute, M3,Leukemia, Progranulocytic,Myeloid Leukemia, Acute, M3,Progranulocytic Leukemia,Promyelocytic Leukemia, Acute,AML M3,Acute Promyelocytic Leukemia,Leukemia, Acute Promyelocytic,M3 ANLL,ANLL, M3,Acute Promyelocytic Leukemias
D015514 Oncogene Proteins, Fusion The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin. Chimeric Oncogene Proteins,Chimeric Proteins, Oncogene,Fusion Proteins, Oncogene,Oncogene Fusion Proteins,Oncogene Proteins, Chimeric,Fusion Oncogene Proteins,Oncogene Chimeric Proteins,Proteins, Chimeric Oncogene,Proteins, Fusion Oncogene,Proteins, Oncogene Chimeric,Proteins, Oncogene Fusion

Related Publications

Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
September 2017, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
September 2012, The Korean journal of hematology,
Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
April 2023, Acta pharmacologica Sinica,
Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
January 2018, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
September 2022, Clinical laboratory,
Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
January 2017, Case reports in hematology,
Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
January 2016, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
August 2019, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
December 2024, Hematology (Amsterdam, Netherlands),
Laura Pardo Gambarte, and Aída Franganillo Suárez, and Javier Cornago Navascués, and Carlos Soto de Ozaeta, and Carlos Blas López, and Mireia Atance Pasarisas, and Rocío Nieves Salgado Sánchez, and Cristina Serrano Del Castillo, and Raquel Mata Serna, and Diego Velasco Rodríguez, and José Luis López-Lorenzo, and Pilar Llamas-Sillero, and Laura Solán Blanco
January 2010, Indian journal of pathology & microbiology,
Copied contents to your clipboard!